Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile of the human leukemia cell line Reh after treatment with bortezomib, valproic acid or a combination of both.

ABSTRACT: New therapy options are required for relapsed B-cell precursor ALL patients in order to improve survival and reduce adverse acute and late effects. We observed a synergistic anti-leukemic activity of concomitant treatment with bortezomib and valproic acid in BCP-ALL cells. In this experiment we aimed to identify the pathways modulated after concomitant treatment with bortezomib and valproic acid.

ORGANISM(S): Homo sapiens

PROVIDER: GSE41951 | GEO | 2013/02/01

SECONDARY ACCESSION(S): PRJNA178578

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression profile of the human leukemia cell line Reh after treatment with bortezomib, valproic acid or a combination of both.

Project description:New therapy options are required for relapsed B-cell precursor ALL patients in order to improve survival and reduce adverse acute and late effects. We observed a synergistic anti-leukemic activity of concomitant treatment with bortezomib and valproic acid in BCP-ALL cells. In this experiment we aimed to identify the pathways modulated after concomitant treatment with bortezomib and valproic acid. Reh cells treated with either bortezomib, valproic acid, or the combination of both normalized to a untreated control.

2013-02-01 | E-GEOD-41951 | biostudies-arrayexpress

Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma

2014-03-13 | GSE55818 | GEO

Transcription profiling of human embryonic stem cells in response to valproic acid and valproic acid analogs

Project description:Transcriptional profiling of valproic acid and valproic acid analogs in human embryonic stem cells.

2010-12-31 | E-MEXP-2374 | biostudies-arrayexpress

Identification differentially expressed genes upon valproic acid treatment

Project description:The goal of this study is to define genes that are differentially expressed in Down syndrome leukemic blasts after treatment with valproic acid (VPA) Here we report the identification gene sets that are downregulated in Down syndrome leukemic cell lines after exposure to valproic acid (VPA)

2011-07-13 | GSE30517 | GEO

Genome-wide expression profiling after Valproic acid treatment in Saccharomyces cerevisiae

Project description:Valproic acid (VA) is a small-chain branched fatty acid, widely used as anticonvulsant, and mood stabilizer to treat psychiatric illness. Valproic acid is also known to inhibit the histone deacetylases (HDACs), which makes it as a potent antitumor agent in alone or in combination with other cytotoxic drugs. Beside its conventional activities, valproic acid reported to have much broader, complicated effects and affect many complex physiological processes. However the molecular mechanisms of valproic acid are unclear. So, we used budding yeast transcriptome analysis to better understand the molecular mechanism of action of valproic acid. The clusters of differentially expressed genes in microarray after VA (6mM) treatment and their functional enrichment analysis revealed its overall effects on various biological processes such as cell cycle, signal transduction, metabolism, transcription, ubiquitination, transporter activities and many more. The microarray data were validated by quantitative real-time PCR.

2016-10-14 | GSE62400 | GEO

Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer

Project description:The purpose of this study is to first determine the maximum tolerated dose of capecitabine given alone or in combination with valproic acid during preoperative short-course radiotherapy (Phase 1). The next part of the study (Phase 2)will explore whether the addition of valproic acid or the addition of capecitabine to short-course radiotherapy, before optimal radical surgery might increase the pathologic complete tumor regression rate in patients with low-moderate risk rectal cancer.

| 2148214 | ecrin-mdr-crc

human placenta-derived cell line (JEG-3): Control vs. valproic acid(VPA)-treated

Project description:Transcriptional profiling of human placenta-derived JEG-3 cell line comparing vehicle control with 7.38 mM of valproic acid(VPA)-treated JEG-3 cells for 48 hr. 7.38 mM valproic acid(VPA) induced the 30% inhibiotion of JEG-3 cell proliferation, G1 phase cell cycle arrest and the reduction of cell size. The Goal was to analyze the mechanism of valproic acid-induced adverse effects in placental cells.

2012-10-11 | GSE41441 | GEO

Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma

Project description:Bortezomib therapy has been proven successful for the treatment of relapsed and/or refractory multiple myeloma (MM). However, both intrinsic and acquired resistance has already been observed. In this study, we explored the relationship between CD9 expression and bortezomib sensitivity in MM Both intrinsic and acquired resistance has already been observed. In this study, we explored the relationship between CD9 expression and bortezomib sensitivity in MM. We found that down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma. A six chip study using total RNA recovered from three separate wild-type cultures of U266 cells and three separate cultures of U266 with CD9 overexpression. Each chip measures the expression level of 45,033 genes from Homo sapiens with fourteen 60-mer probe pairs (PM/MM) per gene, with three-fold technical redundancy.

2014-03-13 | E-GEOD-55818 | biostudies-arrayexpress

Gene expression profile in human hepatoma HepG2 cells induced by gambogic acid and bortezomib

Project description:This experiment is designed to evaluate gene expression alterations following treatment with gambogic acid and bortezomib in human HepG2 cells. We find gambogic acid yielded a similar gene expression profile as did bortezomib.

2012-06-15 | GSE38730 | GEO

human placenta-derived cell line (JEG-3): Control vs. valproic acid(VPA)-treated

2012-10-11 | E-GEOD-41441 | biostudies-arrayexpress